US-based clinical-stage biotechnology company IVIEW Therapeutics Inc announced on Tuesday that it has completed patient recruitment for its Phase 1/2 clinical trial evaluating IVW-1001, a novel TRPM8 agonist delivered through ophthalmic eyelid wipe, intended for the treatment of signs and symptoms of dry eye disease.

The firm expects to report topline data from the trial in the first quarter of 2025.

Houman Hemmati, MD, PhD, IVIEW Therapeutics' chief medical advisor, said: "We are thrilled to have reached this significant milestone in our clinical development program for IVW-1001. Completing patient enrolment brings us one step closer to potentially offering a new therapeutic option for individuals suffering from dry eye disease. We are eagerly awaiting the trial results and remain optimistic about the potential impact on patient care."